Obesity drugs linked to stalling cancer

Emerging research indicates that GLP-1 receptor agonists, popular weight-loss drugs such as Wegovy and Mounjaro, may significantly stall the progression of various cancers.

The study suggests that the drugs' metabolic effects could offer a promising new pathway for oncology treatments by altering the environment in which tumors grow.

While the findings have drawn significant interest from the medical community, experts warn that more long-term clinical trials are needed to confirm the results.

Meanwhile, the European Union has backed a higher-dose version of Wegovy, signaling the continued expansion of these treatments in the global market.